Vivos Therapeutics
VVOS
30 hedge funds and large institutions have $1.71M invested in Vivos Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
172% more capital invested
Capital invested by funds: $630K → $1.71M (+$1.08M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
11% more funds holding
Funds holding: 27 → 30 (+3)
0.53% more ownership
Funds ownership: 0.27% → 0.8% (+0.53%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
+$2.82M |
| 2 |
GGI
Godsey & Gibb Inc
Richmond,
Virginia
|
+$81.4K |
| 3 |
Two Sigma Investments
New York
|
+$79.6K |
| 4 |
Renaissance Technologies
New York
|
+$63.8K |
| 5 |
VF
Virtu Financial
New York
|
+$40.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$30.8K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$25.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.1K |
| 4 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$7.66K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.53K |
VVOS Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2023, worth a combined $1.71M — up 172% from $630K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VVOS positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Strategic Wealth Investment Group, opening a new position worth an estimated $2.82M. The largest seller was Citadel Advisors, exiting entirely with an estimated $30.8K sold.
- 30 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2023, up from 27 in Q4 2022.
- Funds reported $1.71M of Vivos Therapeutics stock for Q1 2023, up 172% quarter-over-quarter.
- 8 funds opened new Vivos Therapeutics positions in Q1 2023 and 5 closed out, a net change of +3 holders.
- The largest Vivos Therapeutics buyer in Q1 2023 was Strategic Wealth Investment Group, an estimated $2.82M added.
- The largest Vivos Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $30.8K sold.
Based on aggregated 13F filings for Q1 2023.